NEW YORK (CNNMoney.com) -- Tercica, a California-based biotechnology company, announced a deal with Genentech Tuesday ... (down $0.01 to $0.79, Charts), based in Richmond, Va., ...

The San Francisco company, which this summer added a handful of Genentech alumni, including former CEO Ian Clark, started a clinical trial in August for its experimental metastatic breast cancer drug.

As for how glofitamab compares to the standard of care in this third-line setting, Laport said historical controls put responses at about 20%, which means Genentech’s offering is “well above t ...

June 30 (Reuters) - Genentech will withdraw Gavreto from use in the United States for treating a type of thyroid cancer as it was not feasible for the Roche (ROG.S), opens new tab unit to pursue ...

February 04, 2025--(BUSINESS WIRE)--Genentech, a member of the Roche Group ... 0.5 mg ranibizumab intravitreal injections (9.6 eye chart letters, similar to gaining two more lines on an eye ...

Biotech leader Genentech built its plant in Vacaville in 1997. Company officials including development facilitator Joaquin Castaneda failed to respond to requests for comment from the Business ...

The complaint said Genentech was previously aware of the patent, noting Roche's opposition to UPenn's related European patent applications, and accused Genentech of infringing willfully.

Genentech’s commitment to diversity and inclusion is also on display in the company's organizational chart, Highsmith said. “While diversity teams are typically housed under the human ...

--(BUSINESS WIRE)--Genentech, a member of the Roche Group ... to monthly ranibizumab injections – +0.2 and +0.5 eye chart letters from baseline, respectively – at weeks 36 and 40 of treatment.

charts, and forecasts on the Digital Health industry with the Digital Health Briefing. You can learn more about subscribing here. Massive pharma company Roche and its subsidiary Genentech ...

--(BUSINESS WIRE)--Genentech, a member of the Roche Group ... correction such as glasses – when reading letters on an eye chart) from baseline at the average of Week 36 and Week 40.

SAN MATEO, Calif. and CAMBRIDGE, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those ...